UBS Group
CLBT icon

UBS Group’s Cellebrite CLBT Stock Holding History

UBS Group’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-402,000
Closed -$3.72M – 10291
2021
Q3 		$3.72M Buy
+402,000
New +$4.2M ﹤0.01% 2984

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

UBS Group's CLBT Position: Q2 2026 in Review

UBS Group reduced its Cellebrite (CLBT) stake by 12% in Q2 2026, selling an estimated $917K and leaving 500,766 shares worth $7.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3791.

UBS Group first reported a position in CLBT in Q3 2021 and has held it in 16 quarters since. The position peaked at $14.4M in Q1 2025. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • UBS Group held 500,766 shares of Cellebrite worth $7.31M as of Q2 2026.
  • UBS Group sold 69,382 Cellebrite shares in Q2 2026, an estimated $917K.
  • Cellebrite made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3791 holding.
  • UBS Group first reported a position in Cellebrite in Q3 2021 and has held it in 16 quarters since.
  • UBS Group's Cellebrite position peaked at $14.4M in Q1 2025.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.